Aug 8 (Reuters) - Keryx Biopharmaceuticals Inc:
* Announces second-quarter net loss of $5.2 million, or 9 cents per share
* 2q loss compares to year-ago net income of $14.1 million, or 29 cents per
share
* 2q results includes $1.4 million increase in research and development
expenses and $0.7 million of non-cash compensation expense related to equity
incentive grants
* CEO: we continued to make 'significant progress' on each of the three phase 3
programs
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about Keryx Biopharmaceuticals Inc click here:) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* Announces second-quarter net loss of $5.2 million, or 9 cents per share
* 2q loss compares to year-ago net income of $14.1 million, or 29 cents per
share
* 2q results includes $1.4 million increase in research and development
expenses and $0.7 million of non-cash compensation expense related to equity
incentive grants
* CEO: we continued to make 'significant progress' on each of the three phase 3
programs
((New York Equities Desk; tel: +1 646 223 6000))
(For more news about Keryx Biopharmaceuticals Inc click here:) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.